VBL Therapeutics Reports Final Phase 1/2 Results Presented At ASCO Showed VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer
Benzinga Newsdesk